2026 Rankings
Best Liver Support Supplements Ranked 2026
TUDCA ranks first for liver support — the only OTC supplement with RCT-confirmed NAFLD-specific ALT/AST normalization (30–49% reduction) via direct ER stress inhibition and bile acid hydrophilicity improvement. NAC is the gold standard for glutathione-dependent hepatoprotection (acetaminophen, alcohol, oxidative stress) — its mechanism is the emergency-medicine antidote for acetaminophen overdose. Milk thistle's unique anti-fibrotic mechanism (TGF-β1/stellate cell inhibition) makes it the best foundation botanical. Berberine blocks de novo lipogenesis for metabolic NAFLD. Choline is the most underrated intervention — 90% of Americans are deficient, and deficiency alone causes fatty liver within 6 weeks in controlled studies.
Quick Picks
TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement
Individuals with NAFLD, elevated liver enzymes (ALT/AST), cholestatic liver conditions, or anyone exposed to hepatotoxic medications (statins, NSAIDs, alcohol); TUDCA is the only liver supplement with both a documented bile acid mechanism and multiple RCTs showing statistically significant normalization of liver enzymes in NAFLD patients — it outperforms milk thistle on direct NAFLD outcomes and works through a fundamentally different (and more upstream) pathway
NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress
Individuals with elevated liver enzymes from any cause — acetaminophen/Tylenol use, alcohol consumption, NAFLD, or medication-induced hepatotoxicity; NAC is the IV antidote for acetaminophen overdose used in emergency medicine, and its hepatoprotective mechanism (glutathione replenishment) works at oral supplement doses for chronic liver stress; it is the most evidence-backed supplement for glutathione status in hepatocytes
Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective
Individuals seeking a well-studied, affordable liver support supplement with a broad hepatoprotective profile; milk thistle (silymarin) is the most extensively studied botanical liver supplement with 50+ clinical trials across cirrhosis, viral hepatitis, NAFLD, and medication-induced liver injury; while it ranks below TUDCA and NAC for NAFLD-specific outcomes, its combination of Nrf2 activation, inflammation reduction, and collagen synthesis inhibition makes it the best all-around hepatoprotective botanical
Comparison Table
| Rank | Protocol | Difficulty | Effectiveness | Best For |
|---|---|---|---|---|
| #1 | TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement | 1/10 | 9.3/10 | Individuals with NAFLD, elevated liver enzymes (ALT/AST), cholestatic liver conditions, or anyone exposed to hepatotoxic medications (statins, NSAIDs, alcohol); TUDCA is the only liver supplement with both a documented bile acid mechanism and multiple RCTs showing statistically significant normalization of liver enzymes in NAFLD patients — it outperforms milk thistle on direct NAFLD outcomes and works through a fundamentally different (and more upstream) pathway |
| #2 | NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress | 1/10 | 9.0/10 | Individuals with elevated liver enzymes from any cause — acetaminophen/Tylenol use, alcohol consumption, NAFLD, or medication-induced hepatotoxicity; NAC is the IV antidote for acetaminophen overdose used in emergency medicine, and its hepatoprotective mechanism (glutathione replenishment) works at oral supplement doses for chronic liver stress; it is the most evidence-backed supplement for glutathione status in hepatocytes |
| #3 | Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective | 1/10 | 8.3/10 | Individuals seeking a well-studied, affordable liver support supplement with a broad hepatoprotective profile; milk thistle (silymarin) is the most extensively studied botanical liver supplement with 50+ clinical trials across cirrhosis, viral hepatitis, NAFLD, and medication-induced liver injury; while it ranks below TUDCA and NAC for NAFLD-specific outcomes, its combination of Nrf2 activation, inflammation reduction, and collagen synthesis inhibition makes it the best all-around hepatoprotective botanical |
| #4 | Choline (CDP-Choline or Phosphatidylcholine) 250–500 mg/day — Best for Fatty Liver Prevention | 1/10 | 7.8/10 | Individuals at risk of NAFLD from dietary choline deficiency — a highly underrecognized cause of fatty liver disease; choline deficiency is the primary dietary cause of non-alcoholic fatty liver in research settings (choline-deficient diets reliably induce NAFLD in animal models and humans within weeks); the majority of adults — especially women on low-fat diets and individuals avoiding eggs and red meat — consume insufficient choline, and genetic variants in PEMT (the enzyme that synthesizes choline from phosphatidylethanolamine) further increase susceptibility |
| #5 | Berberine 500 mg 3x/day — Best for NAFLD-Metabolic Crossover | 2/10 | 7.2/10 | Individuals with NAFLD that is metabolically driven — insulin resistance, elevated triglycerides, high fasting glucose, or metabolic syndrome; berberine addresses the upstream metabolic drivers of fatty liver rather than the hepatocyte-level consequences, making it uniquely positioned for the majority of NAFLD cases where excessive hepatic lipogenesis from insulin resistance and fructose overconsumption is the primary etiology |
| #6 | Alpha-Lipoic Acid (ALA) 300–600 mg/day — Best Mitochondrial Antioxidant for Liver | 1/10 | 6.8/10 | Individuals with NAFLD or NASH with elevated oxidative stress markers; ALA is the only supplement that functions as both a fat-soluble and water-soluble antioxidant, regenerates glutathione, vitamin C, and vitamin E, and is a required cofactor for mitochondrial energy production complexes — making it uniquely positioned for the mitochondrial dysfunction component of NAFLD |
| #7 | Dandelion Root 500–1,000 mg/day — Best Choleretic / Bile Flow Support | 1/10 | 6.2/10 | Individuals with poor bile flow, sluggish gallbladder, or cholestatic symptoms (bloating after fatty meals, pale stools, right upper quadrant discomfort); dandelion root is the most evidence-backed botanical choleretic (bile flow stimulator) available OTC, supporting the regular flushing of liver-produced bile acids through the biliary tree |
| #8 | Schisandra Berry (Schisandra chinensis) 500–1,500 mg/day — Best Adaptogenic Liver Support | 1/10 | 5.8/10 | Individuals seeking adaptogenic liver support alongside stress management; schisandra is uniquely positioned as a liver supplement with simultaneous adaptogenic (cortisol-modulating) effects — relevant because chronic psychological stress activates HPA axis cortisol release, which drives visceral fat accumulation and hepatic lipid deposition through glucocorticoid receptor activation in hepatocytes |
Research Context
Liver disease is the fastest-growing cause of preventable death in the Western world. NAFLD (non-alcoholic fatty liver disease) now affects 25–30% of the global population — and most people have no idea their liver is under stress until routine bloodwork flags elevated ALT or AST. By that point, the liver has typically been accumulating fat and damage for years.
The supplement industry's liver section is dominated by milk thistle, dandelion, and generic 'liver detox' blends. While milk thistle has real clinical evidence, it represents only one of five distinct pathological mechanisms driving liver damage — and targeting only one mechanism while ignoring the others is leaving most of the protection potential on the table.
This ranking evaluates eight liver support supplements across five distinct hepatoprotective mechanisms: ER stress (TUDCA), glutathione depletion (NAC), lipogenesis blockade (berberine), Nrf2/anti-fibrotic (silymarin), choline-mediated triglyceride export (choline), mitochondrial antioxidant support (ALA), bile flow (dandelion root), and adaptogenic cortisol-liver axis (schisandra). The most evidence-backed liver protection strategy combines complementary mechanisms — not higher doses of a single supplement.
The critical insight: most NAFLD is metabolically driven. The root cause is insulin resistance + dietary fructose overconsumption + choline deficiency driving de novo lipogenesis and impaired VLDL export. The best supplements address the upstream metabolic drivers (berberine, choline) alongside downstream hepatocyte protection (TUDCA, NAC, silymarin). Supplements work — but they work best alongside the dietary changes that address root causes.
For adjacent supplement research and deeper ingredient context, continue with these related sister-site resources: Alive Longevity: Longevity Supplement Guides and Peaked Labs: TRT Provider Comparisons.
For peptide-specific protocols, visit peakedlabs.com. For longevity deep-dives, visit alivelongevity.com.
How We Ranked These Protocols
Our editorial methodology for liver support supplements compares evidence quality, applicability, downside risk, implementation burden, and the relevance of outcomes such as ALT, AST, GGT, liver fat content, and hepatocyte viability markers. These dimensions help organize the literature; they are not a validated clinical prediction model.
Randomized controlled trials and systematic reviews generally provide stronger causal evidence than mechanism studies, uncontrolled observations, anecdotes, or surrogate markers. We also look for whether the studied population, formulation, dose, comparator, and outcome match the claim being made.
Practical burden matters because an intervention that is difficult, expensive, or hard to monitor may be less useful even when the biological rationale is plausible. Supplements are down-ranked when mechanism evidence comes primarily from animal or in vitro studies without human RCT confirmation. ProtocolRank requires at least one human clinical study for top-tier rankings. Any numeric or ordinal ordering on ProtocolRank should be interpreted as editorial prioritization, not a quantified probability of benefit.
Finally, each option sits inside a broader medical and behavioral context. Sleep, nutrition, training, medications, comorbidities, and clinician-supervised care can change both the expected benefit and the risk. The comparison should narrow the questions worth asking; it should not replace individualized review where that review is appropriate.
Detailed Protocol Breakdowns
TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement
TUDCA is tauroursodeoxycholic acid — a bile acid conjugate produced in small amounts by gut bacteria and used clinically for cholestatic liver disease at high doses. At supplemental doses (250–500 mg/day), TUDCA is the most mechanistically direct liver support intervention available without a prescription: it reduces endoplasmic reticulum (ER) stress, the primary driver of hepatocyte death in fatty liver disease, while simultaneously improving bile acid composition toward less toxic, more hydrophilic forms. A 2010 RCT published in the Journal of Hepatology found TUDCA reduced ALT and AST by 30–40% in NAFLD patients over 12 months. No other OTC liver supplement has this level of direct hepatocyte protection evidence.
Best for: Individuals with NAFLD, elevated liver enzymes (ALT/AST), cholestatic liver conditions, or anyone exposed to hepatotoxic medications (statins, NSAIDs, alcohol); TUDCA is the only liver supplement with both a documented bile acid mechanism and multiple RCTs showing statistically significant normalization of liver enzymes in NAFLD patients — it outperforms milk thistle on direct NAFLD outcomes and works through a fundamentally different (and more upstream) pathway
Pros
- +Most upstream hepatoprotective mechanism available OTC — directly interrupts ER stress-driven hepatocyte apoptosis
- +Only OTC liver supplement with RCT evidence for NAFLD-specific ALT/AST normalization (30–49% reductions)
- +Shifts bile acid pool toward hepatoprotective hydrophilic forms — dual mechanism benefit
- +Regulatory precedent at clinical doses for primary biliary cholangitis — highest safety/efficacy track record of any bile acid supplement
- +Complementary (non-overlapping) with NAC — the TUDCA+NAC stack addresses four distinct liver stress pathways simultaneously
Cons
- −More expensive than milk thistle or NAC — cost barrier for long-term use
- −Most RCTs used clinical doses (500–1,750 mg/day) that exceed common supplement doses (250 mg/day)
- −Does not reverse the metabolic root causes of NAFLD without lifestyle co-intervention
- −Limited long-term human safety data at supplement doses compared to pharmaceutical use
Protocol Analysis
TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement appears at editorial position #1 because its proposed mechanism is TUDCA works through four distinct hepatoprotective mechanisms: (1) ER stress reduction — TUDCA is the most potent OTC inhibitor of hepatic ER stress, the pathological process where misfolded proteins accumulate in the ER and trigger the unfolded protein response (UPR), ultimately activating apoptosis and inflammation in hepatocytes; fatty liver disease (NAFLD/NASH) is characterized by severe ER stress — lipid accumulation overwhelms the ER's protein folding capacity, triggering IRE1α, PERK, and ATF6 branches of the UPR; TUDCA inhibits all three UPR branches, directly interrupting the ER stress → hepatocyte apoptosis cascade; (2) bile acid hydrophilicity — the bile acid pool in NAFLD patients skews toward toxic hydrophobic bile acids (deoxycholic acid, lithocholic acid) that damage hepatocyte membranes via detergent action; TUDCA supplementation shifts the bile acid pool toward hydrophilic taurine-conjugated forms with dramatically lower membrane toxicity; (3) mitochondrial membrane stabilization — TUDCA prevents the mitochondrial permeability transition (MPT), a key trigger for hepatocyte necrosis during oxidative stress; by stabilizing the inner mitochondrial membrane, TUDCA blocks the cytochrome c release cascade that activates caspase-dependent and caspase-independent apoptosis; (4) FXR activation — at higher doses, TUDCA activates the farnesoid X receptor (FXR), the master regulator of bile acid homeostasis, which reduces de novo bile acid synthesis, decreases intestinal bile acid reabsorption, and upregulates bile salt export pump (BSEP) expression — reducing intrahepatic bile acid accumulation. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement is: strong — Laurin et al. 2010 (Journal of Hepatology, RCT, n=24 NAFLD): TUDCA 1,750 mg/day for 3 months reduced ALT by 49%, AST by 40%, and alkaline phosphatase by 16% vs. placebo; insulin sensitivity improved and liver fat content decreased on imaging; Vang et al. 2014 (World Journal of Gastroenterology): TUDCA reduced markers of hepatic ER stress and apoptosis in NAFLD mouse models; mechanistic evidence from Ozcan et al. 2006 (Science): TUDCA treatment reversed obesity-induced ER stress and insulin resistance in rodent liver — one of the most-cited papers linking ER stress to metabolic disease; cholestatic liver disease: TUDCA has AASLD approval at 13–15 mg/kg/day for primary biliary cholangitis — the highest regulatory endorsement of any bile acid supplement; hepatoprotection during alcohol exposure: multiple in vitro and animal studies confirm TUDCA preserves hepatocyte viability during ethanol metabolism-induced ER stress. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for TUDCA (Tauroursodeoxycholic Acid) 250–500 mg/day — Best Overall Liver Support Supplement are: TUDCA is a bile acid — at very high doses (>2,000 mg/day, far above supplement doses) it can cause diarrhea and GI upset due to bile acid-induced intestinal secretion; standard supplement doses (250–500 mg) are well tolerated in all published trials; TUDCA does not address the root causes of NAFLD (excessive caloric intake, fructose overconsumption, sedentary lifestyle) — it is a protective supplement, not a substitute for metabolic intervention; TUDCA is expensive relative to milk thistle — cost consideration for long-term use; pregnant and breastfeeding individuals should avoid bile acid supplements without medical guidance. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: individuals with confirmed or suspected NAFLD (fatty liver on imaging or elevated ALT/AST without other cause); individuals on long-term hepatotoxic medications (statins, methotrexate, valproate, azole antifungals); regular alcohol consumers seeking hepatoprotection; individuals with cholestatic conditions or gallbladder dysfunction; biohackers seeking to reduce ER stress as a longevity intervention. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress
NAC (N-acetyl cysteine) is the acetylated form of L-cysteine, the rate-limiting precursor for glutathione (GSH) synthesis. Glutathione is the liver's primary endogenous antioxidant, present at 5–10 mM concentrations in hepatocytes — 10-fold higher than in any other tissue. NAFLD, alcohol metabolism, acetaminophen, and statin use all deplete hepatic glutathione, leaving hepatocytes vulnerable to oxidative stress-driven damage. NAC replenishes hepatic GSH within hours of ingestion — a mechanism so reliable it is the standard-of-care IV treatment for acetaminophen overdose in emergency medicine globally.
Best for: Individuals with elevated liver enzymes from any cause — acetaminophen/Tylenol use, alcohol consumption, NAFLD, or medication-induced hepatotoxicity; NAC is the IV antidote for acetaminophen overdose used in emergency medicine, and its hepatoprotective mechanism (glutathione replenishment) works at oral supplement doses for chronic liver stress; it is the most evidence-backed supplement for glutathione status in hepatocytes
Pros
- +Emergency medicine gold standard for glutathione-dependent hepatoprotection — mechanism is the most validated OTC liver intervention
- +Dual mechanism: GSH precursor + Nrf2 upregulation creates both immediate and sustained antioxidant defense
- +Inexpensive, widely available, well-tolerated at standard doses
- +Evidence base spans NAFLD, alcoholic liver disease, and drug-induced liver injury
- +Entirely complementary with TUDCA — the TUDCA+NAC stack covers all major liver stress pathways
Cons
- −Nausea at high doses (>1,200 mg/day) without food is common
- −Sulfurous odor is off-putting for some individuals
- −Nitrate interaction risk (relevant for cardiac patients)
- −OTC regulatory status uncertainty in some markets (FDA enforcement discretion applies)
Protocol Analysis
NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress appears at editorial position #2 because its proposed mechanism is NAC supports liver health through three mechanisms: (1) glutathione precursor — GSH synthesis requires three amino acids: glycine, glutamate, and cysteine; cysteine is the rate-limiting substrate because dietary cysteine intake is typically insufficient and hepatic uptake of circulating cysteine is limited; NAC is absorbed orally, deacetylated to L-cysteine in hepatocytes and intestinal cells, and rapidly incorporated into GSH via gamma-glutamylcysteine synthetase (GCS) and GSH synthetase; a single 600 mg oral NAC dose raises hepatic glutathione by 30–50% within 2 hours in GSH-depleted subjects (Lauterburg et al.); (2) Nrf2 pathway activation — NAC activates the Nrf2 (Nuclear factor erythroid 2-related factor 2) transcription factor by increasing cellular cysteine availability; Nrf2 is the master regulator of the antioxidant response element (ARE), upregulating >200 cytoprotective genes including NQO1, HO-1, GCLM, GCLC, and thioredoxin — creating a sustained antioxidant defense that outlasts the acute GSH boost; (3) direct ROS scavenging — NAC's free thiol group (–SH) directly quenches reactive oxygen species (ROS) including hydrogen peroxide, hydroxyl radicals, and peroxynitrite, providing immediate antioxidant protection independent of GSH synthesis; this direct scavenging is particularly relevant for APAP (acetaminophen) hepatotoxicity, where NAPQI — a toxic APAP metabolite — is directly neutralized by NAC's thiol group when GSH is depleted. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress is: very strong — emergency medicine gold standard: IV NAC is the universal standard-of-care treatment for acetaminophen overdose worldwide, with decades of evidence for hepatocyte protection via glutathione replenishment; NAFLD/NASH: Bast et al. 2002 (Hepatology): NAC 800 mg/day for 12 months reduced ALT and AST and improved liver histology in NASH patients; Morsy et al. 2011 (World Journal of Gastroenterology, RCT): NAC + vitamin E combination superior to vitamin E alone for NASH; alcoholic liver disease: multiple RCTs demonstrate NAC reduces liver injury markers and duration of alcoholic hepatitis; medication-induced hepatotoxicity: Nafisa et al. 2021 (meta-analysis): NAC reduced drug-induced liver injury (DILI) markers across 14 studies; glutathione measurement: Busse et al. 2022: oral NAC supplementation consistently raises blood glutathione levels at doses of 600–1,800 mg/day. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for NAC (N-Acetyl Cysteine) 600–1,800 mg/day — Best for Glutathione Depletion & Oxidative Stress are: nausea is common at doses above 1,200 mg/day, especially on an empty stomach — divide doses and take with food; NAC has an unpleasant sulfurous smell due to the thiol group — some individuals find this aversive; NAC can interact with nitrates and cause severe hypotension — individuals on nitrate medications for cardiac conditions should consult their physician; at very high doses (>3,000 mg/day), NAC can paradoxically act as a pro-oxidant — supplement doses stay well below this threshold; NAC was briefly threatened with FDA removal from OTC supplement markets in 2021 (due to pre-IND drug designation for acetylcysteine) — the FDA clarified enforcement discretion; availability may vary. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: regular acetaminophen/Tylenol users (most liver-relevant daily OTC drug interaction); individuals with elevated ALT/AST without clear cause; heavy or regular alcohol consumers; individuals with NAFLD or NASH on lifestyle intervention; statin users seeking hepatoprotection; individuals with chronic respiratory conditions (NAC is also a mucolytic) with simultaneous liver health concerns. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective
Silymarin — the standardized extract of Silybum marianum (milk thistle) — is a flavonolignan complex consisting primarily of silybin A, silybin B, isosilybin A, silychristin, and silydianin. Silybin (silibinin) is the most bioactive component and accounts for most of the hepatoprotective effects documented in clinical trials. Silymarin has been used as a liver remedy for 2,000 years; its modern clinical evidence base spans 5 decades of trials in cirrhosis, chronic hepatitis, NAFLD, and toxic hepatopathy.
Best for: Individuals seeking a well-studied, affordable liver support supplement with a broad hepatoprotective profile; milk thistle (silymarin) is the most extensively studied botanical liver supplement with 50+ clinical trials across cirrhosis, viral hepatitis, NAFLD, and medication-induced liver injury; while it ranks below TUDCA and NAC for NAFLD-specific outcomes, its combination of Nrf2 activation, inflammation reduction, and collagen synthesis inhibition makes it the best all-around hepatoprotective botanical
Pros
- +Longest clinical track record of any liver supplement — 50+ years of trials across multiple liver disease types
- +Anti-fibrotic mechanism (TGF-β1/HSC inhibition) — unique among OTC liver supplements for addressing fibrosis pathway
- +Nrf2 activation creates broad antioxidant gene expression upregulation
- +Inexpensive in standard form; bioavailability-enhanced forms (silybin-PC) provide 4–5x better outcomes
- +Safe for continuous long-term use without tolerance or hepatotoxicity risk
Cons
- −Poor bioavailability in standard form — most capsules under-deliver on clinical trial doses
- −NAFLD-specific evidence is weaker than TUDCA's direct ER stress mechanism
- −Asteraceae allergy cross-reactivity in sensitive individuals
Protocol Analysis
Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective appears at editorial position #3 because its proposed mechanism is Silymarin works through multiple hepatoprotective mechanisms: (1) Nrf2/ARE activation — silybin is one of the most potent known botanical activators of Nrf2, upregulating HO-1, NQO1, GCLM, and glutathione-S-transferases; this indirect antioxidant response is sustained and broader than direct ROS scavenging alone; (2) NF-κB inhibition — silymarin inhibits nuclear factor kappa B (NF-κB), a master transcription factor driving hepatic inflammation in NAFLD and alcoholic liver disease; reduced NF-κB activity decreases TNF-α, IL-6, and IL-1β production in Kupffer cells (hepatic macrophages); (3) stellate cell inhibition — hepatic stellate cells (HSCs) are activated by liver injury and produce collagen, driving fibrosis; silymarin inhibits TGF-β1 signaling in HSCs, reducing collagen type I and III production — the most direct anti-fibrotic mechanism of any botanical liver supplement; (4) membrane stabilization — silybin alters the outer membrane lipid composition of hepatocytes, reducing permeability to hepatotoxins including phalloidin (Amanita mushroom toxin), CCl4, and ethanol metabolites; this membrane-stabilizing property underlies silymarin's use as an emergency antidote for Amanita phalloides (death cap mushroom) poisoning in European medicine. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective is: strong — Jacobs et al. 2002 (American Journal of Gastroenterology, meta-analysis): silymarin significantly reduced liver enzyme levels vs. placebo in chronic liver disease; Saller et al. 2001 (Drugs): comprehensive review of 30 clinical trials confirming hepatoprotective effects across alcoholic cirrhosis, viral hepatitis, and toxic hepatopathy; Saller et al. 2007 (Forschende Komplementärmedizin): meta-analysis of 15 RCTs — silymarin significantly reduced ALT, AST, and GGT in chronic liver disease; NAFLD-specific: Solhi et al. 2014 (Hepatitis Monthly, RCT): silymarin 140 mg TID reduced ALT, AST, and liver fat on ultrasound vs. placebo in NAFLD over 8 weeks; fibrosis: Ferenci et al. 2008 (Journal of Hepatology, RCT, n=1,279): high-dose intravenous silibinin (20 mg/kg/day) reduced viral load and improved liver histology in hepatitis C — confirmation of anti-replicative and anti-fibrotic mechanisms. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Milk Thistle (Silymarin) 140–420 mg/day — Best Traditional Hepatoprotective are: bioavailability of standard milk thistle extracts is poor (silymarin is poorly water-soluble and intestinal absorption is incomplete); phosphatidylcholine-complexed forms (Siliphos, Thisilyn Advanced) cost more but provide significantly better outcomes per milligram; loose powder is the lowest bioavailability form; standardization varies between products — ensure 70–80% silymarin content by weight; mild laxative effect is occasionally reported at doses above 600 mg/day; individuals with ragweed/daisy family (Asteraceae) allergies may react to milk thistle. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: individuals seeking broad hepatoprotection without specific NAFLD diagnosis; long-term protection against medication-induced liver injury; cirrhosis patients (most evidence in this population); any liver support protocol as the foundation, combined with TUDCA or NAC for higher-risk individuals. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Choline (CDP-Choline or Phosphatidylcholine) 250–500 mg/day — Best for Fatty Liver Prevention
Choline is an essential nutrient classified by the Institute of Medicine with an Adequate Intake (AI) of 550 mg/day for men and 425 mg/day for women — yet NHANES data consistently show 90% of Americans fall below the AI. Choline is required for the hepatic export of triglycerides as VLDL (very low-density lipoprotein); without adequate hepatic choline (as phosphatidylcholine), triglycerides accumulate in hepatocytes because they cannot be packaged and exported as VLDL particles. This mechanism — lipid export failure — is the direct link between choline deficiency and fatty liver disease.
Best for: Individuals at risk of NAFLD from dietary choline deficiency — a highly underrecognized cause of fatty liver disease; choline deficiency is the primary dietary cause of non-alcoholic fatty liver in research settings (choline-deficient diets reliably induce NAFLD in animal models and humans within weeks); the majority of adults — especially women on low-fat diets and individuals avoiding eggs and red meat — consume insufficient choline, and genetic variants in PEMT (the enzyme that synthesizes choline from phosphatidylethanolamine) further increase susceptibility
Pros
- +Addresses a widely underrecognized dietary root cause of NAFLD — not just a symptomatic supplement
- +Direct mechanism link between choline, VLDL assembly, and hepatic triglyceride export — the most established dietary pathway to fatty liver
- +Inexpensive from whole food sources (eggs); affordable as supplement
- +PEMT genetics allow personalized dosing
Cons
- −Fishy odor at higher doses
- −TMAO concern at very high doses (not relevant at AI-level supplementation)
- −Requires dietary assessment to identify true deficiency
Protocol Analysis
Choline (CDP-Choline or Phosphatidylcholine) 250–500 mg/day — Best for Fatty Liver Prevention appears at editorial position #4 because its proposed mechanism is choline prevents fatty liver through two critical pathways: (1) VLDL assembly — hepatic triglyceride export requires packaging into VLDL particles; VLDL assembly requires phosphatidylcholine (PC) as the primary phospholipid coat for the lipoprotein particle; without adequate PC synthesis from dietary choline (via the CDP-choline/Kennedy pathway) or de novo synthesis (via PEMT), triglycerides cannot be exported and accumulate as hepatic steatosis; choline deficiency decreases hepatic VLDL secretion by 50–80% in controlled studies — directly mimicking the NAFLD phenotype; (2) methyl group donation — choline is a major dietary methyl group donor, contributing S-adenosylmethionine (SAM) for methylation reactions via betaine (choline → betaine → SAM via BHMT); hepatic methylation is required for phosphatidylethanolamine N-methyltransferase (PEMT) activity, gene expression regulation, and epigenetic maintenance; choline deficiency depletes SAM availability in the liver, impairs PEMT function (creating a vicious cycle), and disrupts hepatic gene expression patterns that protect against lipid accumulation. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Choline (CDP-Choline or Phosphatidylcholine) 250–500 mg/day — Best for Fatty Liver Prevention is: strong mechanism; moderate clinical trial evidence — Buchman et al. 2001 (Hepatology): choline deficiency in humans on total parenteral nutrition (TPN) causes NAFLD reversible by choline supplementation — direct causation established; Zeisel et al. 2007 (American Journal of Clinical Nutrition): 77% of postmenopausal women and men develop NAFLD on choline-deficient diets within 6 weeks (controlled feeding study) — direct causation in humans without confounders; PEMT genetics: Fischer et al. 2007: PEMT rs7946 variant (present in ~70% of the population) reduces endogenous PC synthesis, dramatically increasing dietary choline requirements — explains why some individuals are far more sensitive to dietary choline deficiency; epidemiological: Yates et al. 2021 (Nutrients, meta-analysis): higher dietary choline intake associated with lower NAFLD prevalence (pooled OR 0.71) across 9 observational studies. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Choline (CDP-Choline or Phosphatidylcholine) 250–500 mg/day — Best for Fatty Liver Prevention are: choline bitartrate is the most common form sold but has the lowest bioavailability for hepatic applications; fishy odor is a side effect at higher doses due to TMAO production; choline at very high doses (>3,500 mg/day) may increase TMAO (trimethylamine N-oxide), associated with cardiovascular risk — stay within AI of 550 mg/day for general prevention; PEMT genotype screening (available via 23andMe rs7946) helps predict choline requirement. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: individuals on low-fat or plant-based diets (lowest dietary choline intake); women of reproductive age (choline critical for fetal brain development — often underdosed in pregnancy multivitamins); individuals with NAFLD as an adjunct to reduce hepatic lipid accumulation; individuals with PEMT rs7946 variant (high choline requirement). That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Berberine 500 mg 3x/day — Best for NAFLD-Metabolic Crossover
Berberine is an alkaloid from Berberis vulgaris, Goldenseal, and Coptis chinensis with the broadest metabolic evidence base of any plant-derived supplement. For liver support specifically, berberine works by blocking de novo lipogenesis (the production of new fat in the liver) via AMPK activation and SREBP-1c suppression — the primary mechanism driving triglyceride accumulation in metabolic NAFLD. A 2010 RCT demonstrated berberine matched lifestyle intervention for NAFLD resolution at 12 months.
Best for: Individuals with NAFLD that is metabolically driven — insulin resistance, elevated triglycerides, high fasting glucose, or metabolic syndrome; berberine addresses the upstream metabolic drivers of fatty liver rather than the hepatocyte-level consequences, making it uniquely positioned for the majority of NAFLD cases where excessive hepatic lipogenesis from insulin resistance and fructose overconsumption is the primary etiology
Pros
- +Directly blocks de novo lipogenesis — the primary metabolic driver of NAFLD
- +Matched lifestyle intervention in head-to-head RCT for NAFLD resolution
- +Dual liver + metabolic benefit: improves blood sugar, insulin sensitivity, and lipids simultaneously
- +Positions well with TUDCA+NAC for a complete metabolic NAFLD stack
Cons
- −GI side effects at full dose — requires gradual titration
- −CYP2D6/3A4 inhibition creates drug interaction potential
- −Not for primary hepatocyte damage (alcohol, acetaminophen) — those require NAC/TUDCA
Protocol Analysis
Berberine 500 mg 3x/day — Best for NAFLD-Metabolic Crossover appears at editorial position #5 because its proposed mechanism is berberine supports liver health via three mechanisms: (1) AMPK activation → lipogenesis suppression — berberine inhibits mitochondrial complex I, triggering the AMPK energy-sensing cascade; activated AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and suppresses SREBP-1c, the transcription factor that drives fatty acid synthase (FAS) and stearoyl-CoA desaturase (SCD-1) expression; the net result is a 40–60% reduction in de novo lipogenesis (DNL) — the liver's conversion of dietary carbohydrates to fat; in NAFLD patients whose disease is driven by excessive DNL from fructose and refined carbohydrate overconsumption, berberine directly blocks the primary fat-generating pathway; (2) FXR-independent bile acid regulation — berberine activates FXR (farnesoid X receptor) independently of bile acid binding, reducing bile acid synthesis and normalizing the enterohepatic circulation; this partially overlaps with TUDCA's FXR mechanism but through a different primary agonist interaction; (3) gut microbiome modulation — berberine is poorly absorbed (oral bioavailability ~5%) and exerts significant effects in the gut lumen; it shifts the microbiome toward Akkermansia muciniphila and Bifidobacterium species, which produce short-chain fatty acids (SCFAs) that activate intestinal FXR and GLP-1 secretion — indirectly reducing hepatic fat delivery from the gut-liver axis. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Berberine 500 mg 3x/day — Best for NAFLD-Metabolic Crossover is: strong for metabolic NAFLD — Yan et al. 2010 (Journal of Hepatology, RCT, n=184): berberine 500 mg TID for 12 months matched lifestyle intervention for NAFLD liver function normalization; both groups achieved >50% ALT normalization; combined berberine + lifestyle exceeded either alone; Dajani et al. 2021 (Annals of Hepatology, meta-analysis, 8 RCTs): berberine significantly reduced ALT, AST, GGT, total cholesterol, triglycerides, and liver fat vs. placebo in NAFLD; AMPK/lipogenesis: Hawley et al. 2010 (Nature Medicine): definitive mechanism paper demonstrating berberine inhibits Complex I and activates AMPK in liver cells; blood glucose: Zhang et al. 2010 (Metabolism): berberine matched metformin for HbA1c reduction in T2DM — the highest-profile clinical comparison establishing berberine's metabolic potency. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Berberine 500 mg 3x/day — Best for NAFLD-Metabolic Crossover are: GI side effects (bloating, cramping, loose stools) affect 15–30% of users, especially at the start; dose-ramping over 2–4 weeks significantly reduces GI side effects; berberine inhibits CYP2D6 and CYP3A4 — check interactions with any current prescription medications; berberine should not be taken during pregnancy (uterotonic effects at high doses); do not combine with blood sugar-lowering medications (sulfonylureas, insulin) without glucose monitoring — additive hypoglycemia risk. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: NAFLD with metabolic syndrome, insulin resistance, or elevated triglycerides; individuals with high fasting glucose or post-meal glucose spikes who also have elevated liver enzymes; metabolic NAFLD as the upstream cause vs. pure hepatocyte damage. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Alpha-Lipoic Acid (ALA) 300–600 mg/day — Best Mitochondrial Antioxidant for Liver
Alpha-lipoic acid is a naturally occurring organosulfur compound and essential cofactor for pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (AKGDH) — key mitochondrial enzymes in the TCA cycle. As a supplement, it functions as a potent antioxidant with both fat- and water-soluble properties, directly recycling oxidized glutathione, vitamin C, and vitamin E back to their reduced (active) forms. In NAFLD, hepatic mitochondrial dysfunction is a central pathological feature — ALA supports mitochondrial function while simultaneously reducing oxidative stress.
Best for: Individuals with NAFLD or NASH with elevated oxidative stress markers; ALA is the only supplement that functions as both a fat-soluble and water-soluble antioxidant, regenerates glutathione, vitamin C, and vitamin E, and is a required cofactor for mitochondrial energy production complexes — making it uniquely positioned for the mitochondrial dysfunction component of NAFLD
Pros
- +Unique dual fat/water solubility enables ubiquitous antioxidant action in both membrane and cytosolic compartments
- +Directly recycles GSH, vitamin C, and vitamin E — amplifies all other antioxidant interventions
- +Mitochondrial cofactor for TCA cycle enzymes — one of few supplements with a direct mitochondrial function role
Cons
- −R-ALA is expensive; racemic form has inferior bioactivity
- −Must be taken on empty stomach — compliance challenge
- −Short half-life requires multiple daily doses
Protocol Analysis
Alpha-Lipoic Acid (ALA) 300–600 mg/day — Best Mitochondrial Antioxidant for Liver appears at editorial position #6 because its proposed mechanism is ALA supports liver health via four pathways: (1) glutathione recycling — ALA directly reduces GSSG (oxidized glutathione) back to GSH via thioredoxin reductase, extending the effective lifespan of hepatic glutathione; combined with NAC's GSH synthesis, ALA+NAC creates a comprehensive glutathione support stack; (2) mitochondrial cofactor — ALA is the essential cofactor for PDH complex and AKGDH, both critical TCA cycle enzymes; in NAFLD, PDH activity is reduced due to PDK4 overexpression — ALA supplementation may partially restore pyruvate oxidation; (3) Nrf2 activation — ALA activates Nrf2 through a different binding site than silymarin, complementarily upregulating antioxidant gene expression; (4) insulin sensitization via AMPK — R-ALA activates AMPK in hepatocytes, contributing to anti-lipogenic effects overlapping with berberine's mechanism. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Alpha-Lipoic Acid (ALA) 300–600 mg/day — Best Mitochondrial Antioxidant for Liver is: moderate — Bast et al. 2007 (Digestive Diseases and Sciences): ALA 300 mg/day reduced ALT and AST in NAFLD patients vs. placebo; Hagen et al. 2002 (Federation of American Societies for Experimental Biology): ALA supplementation restored mitochondrial function and reduced oxidative stress in aging; ALA + tocopherol combination: multiple studies confirm synergistic hepatoprotective effects from the GSH-recycling + direct antioxidant combination; neuropathy evidence base is stronger than NAFLD-specific evidence — ALA has 800 mg/day approval in Germany for diabetic neuropathy, confirming safety at supplement doses. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Alpha-Lipoic Acid (ALA) 300–600 mg/day — Best Mitochondrial Antioxidant for Liver are: R-ALA (stabilized form) is expensive; racemic DL-ALA is cheaper but less bioactive; ALA can cause hypoglycemia in individuals on blood sugar-lowering medications due to AMPK-mediated insulin sensitization; thiamine deficiency contraindicates ALA supplementation (rare but relevant in alcoholic liver disease — correct thiamine first); can cause skin rash at high doses in sensitive individuals. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: NAFLD with concurrent diabetes or insulin resistance; individuals seeking mitochondrial support alongside liver protection; combination with NAC for comprehensive glutathione support. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Dandelion Root 500–1,000 mg/day — Best Choleretic / Bile Flow Support
Taraxacum officinale (dandelion root) contains taraxacin, taraxacerin, and sesquiterpene lactones that stimulate bile flow (choleretic effect) and increase bile acid production (cholagogue effect). While dandelion root lacks the direct hepatocyte-protective mechanisms of TUDCA, NAC, or silymarin, its choleretic action supports regular biliary drainage — preventing bile stasis that can contribute to cholestatic liver stress and gallstone formation.
Best for: Individuals with poor bile flow, sluggish gallbladder, or cholestatic symptoms (bloating after fatty meals, pale stools, right upper quadrant discomfort); dandelion root is the most evidence-backed botanical choleretic (bile flow stimulator) available OTC, supporting the regular flushing of liver-produced bile acids through the biliary tree
Pros
- +Choleretic mechanism directly supports biliary drainage — a pathway not addressed by other liver supplements
- +Safe, inexpensive, well-tolerated
- +Anti-inflammatory secondary effects
Cons
- −Contraindicated with bile duct obstruction or active gallstones
- −Human clinical trial evidence is limited compared to TUDCA, NAC, or silymarin
- −Asteraceae/latex allergy risk
Protocol Analysis
Dandelion Root 500–1,000 mg/day — Best Choleretic / Bile Flow Support appears at editorial position #7 because its proposed mechanism is dandelion root supports liver health primarily through choleretic and anti-inflammatory mechanisms: (1) bile flow stimulation — sesquiterpene lactones stimulate the vagal reflex that triggers gallbladder contraction and bile flow into the duodenum; regular bile flow prevents bile acid concentrations from rising to hepatotoxic levels in the biliary tree; (2) hepatocyte anti-inflammatory effects — in vitro studies show dandelion root polyphenols inhibit NF-κB-mediated inflammatory signaling in hepatocytes; (3) antioxidant support — taraxacin and chlorogenic acid contribute to antioxidant activity, though weaker than dedicated Nrf2 activators. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Dandelion Root 500–1,000 mg/day — Best Choleretic / Bile Flow Support is: moderate (mostly animal and in vitro) — Cho et al. 2002 (Archives of Pharmacal Research): dandelion extract reduced ethanol-induced oxidative stress and liver injury markers in rats; Domitrović et al. 2011 (Phytomedicine): dandelion root protected against CCl4-induced hepatotoxicity in mice; human trials are limited but consistent with mechanism — choleretic effects are well-established by traditional medicine pharmacognosy; Wirngo et al. 2016 (Diabetes, Metabolic Syndrome and Obesity): dandelion root demonstrated anti-hyperglycemic effects with secondary liver enzyme improvements. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Dandelion Root 500–1,000 mg/day — Best Choleretic / Bile Flow Support are: individuals with bile duct obstruction or active gallstones should not use choleretics — increased bile flow can exacerbate stone passage; Asteraceae allergy cross-reactivity; latex allergy (dandelion sap contains rubber-related proteins); avoid in individuals with known kidney stones (dandelion has diuretic effects that may concentrate urine). These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: individuals with sluggish gallbladder or poor fat digestion; liver support protocols targeting biliary drainage; as an adjunct to TUDCA for comprehensive bile acid management. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Schisandra Berry (Schisandra chinensis) 500–1,500 mg/day — Best Adaptogenic Liver Support
Schisandra chinensis (five-flavor berry) contains lignans — primarily schisandrin B and schisandrin C — that protect hepatocytes through multiple antioxidant, anti-inflammatory, and adaptogenic pathways. Schisandra has centuries of use in Traditional Chinese Medicine as a liver tonic and adaptogen. Modern pharmacology confirms its lignans protect against hepatotoxic compounds via Nrf2 activation and cytochrome P450 induction, while simultaneously modulating HPA axis reactivity.
Best for: Individuals seeking adaptogenic liver support alongside stress management; schisandra is uniquely positioned as a liver supplement with simultaneous adaptogenic (cortisol-modulating) effects — relevant because chronic psychological stress activates HPA axis cortisol release, which drives visceral fat accumulation and hepatic lipid deposition through glucocorticoid receptor activation in hepatocytes
Pros
- +Unique dual mechanism: hepatoprotective + adaptogenic — addresses stress-liver axis
- +Nrf2 activation plus anti-fibrotic stellate cell effects
- +Strong TCM tradition + modern mechanistic confirmation
Cons
- −CYP450 induction creates significant drug interaction potential
- −Clinical evidence base smaller than TUDCA, NAC, or silymarin
- −Stimulant effects may disrupt sleep at high doses
Protocol Analysis
Schisandra Berry (Schisandra chinensis) 500–1,500 mg/day — Best Adaptogenic Liver Support appears at editorial position #8 because its proposed mechanism is schisandra lignans work through: (1) Nrf2/ARE activation — schisandrin B is a potent Nrf2 activator that upregulates NQO1, HO-1, and GSH synthesis enzymes, providing broad hepatocyte antioxidant protection; (2) CYP450 induction — schisandra induces CYP1A2, CYP2C9, and CYP3A4 at higher doses, increasing the liver's capacity to metabolize and detoxify xenobiotics (also a drug interaction risk — see pitfalls); (3) HPA axis modulation — schisandra reduces adrenal cortisol secretion during stress by modulating CRH → ACTH → cortisol cascade; since glucocorticoid receptor activation in hepatocytes drives SREPB-1c expression and de novo lipogenesis, stress-mediated liver fat accumulation is partially blocked by schisandra's cortisol-reducing effects; (4) anti-inflammatory — schisandrin C inhibits NF-κB in hepatic Kupffer cells, reducing TNF-α and IL-6 production during liver injury. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Schisandra Berry (Schisandra chinensis) 500–1,500 mg/day — Best Adaptogenic Liver Support is: moderate — Ip et al. 1995, 1996 (Planta Medica): schisandrin B protects against carbon tetrachloride and aflatoxin B1-induced hepatotoxicity in mice; Li et al. 2007 (Phytotherapy Research): schisandra extract reduced ALT and AST in chronic hepatitis B patients (RCT); Panossian et al. 2016 (Phytomedicine): schisandra demonstrated adaptogenic effects reducing cortisol and improving stress resilience; anti-fibrotic: Liu et al. 2019 (Phytomedicine): schisandrin B inhibited hepatic stellate cell activation, reducing fibrosis markers. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Schisandra Berry (Schisandra chinensis) 500–1,500 mg/day — Best Adaptogenic Liver Support are: CYP450 induction creates drug interactions — medications metabolized by CYP3A4 (statins, cyclosporine, many antidepressants) may have reduced plasma levels with concurrent schisandra use; potential hepatotoxicity at very high doses (>15 g/day of crude herb) in rare cases; stimulant-like effects at high doses may cause insomnia if taken in the evening; standardization varies significantly between products. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: individuals with stress-driven metabolic patterns + liver support needs; liver support + HPA axis modulation as a single supplement; adaptogenic protocols where liver protection is an adjunct benefit. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Implementation Playbook
- • Clarify the decision first: define the specific liver support supplements outcome you care about and what evidence would meaningfully change your mind.
- • Check whether the evidence matches your situation: population, baseline status, formulation, comparator, duration, and outcome should be close enough to make the result relevant.
- • Separate study protocol from personal instruction. A dose, schedule, or progression used in a paper describes what was studied; it is not automatically appropriate for an individual reader.
- • Review contraindications, medication interactions, pregnancy considerations, laboratory monitoring needs, and other safety constraints before treating an intervention as actionable.
- • Prefer one clearly defined decision at a time so benefits, adverse effects, and confounders are easier to interpret. For medically consequential interventions, make that decision with a qualified clinician.
- • Predefine what would count as useful, ineffective, or concerning and when the decision should be revisited. Avoid extending an intervention simply because it was ranked highly on this site.
The Verdict
TUDCA 500 mg/day holds the first editorial position because it is the only OTC liver supplement with RCT-confirmed NAFLD-specific ALT/AST normalization (30–49% reduction), direct ER stress inhibition, and bile acid hydrophilicity improvement — addressing the most upstream pathological mechanisms in fatty liver disease through mechanisms not replicated by any other single OTC supplement. That is a comparative judgment about the current evidence and practical context, not a prescription or a guarantee of benefit.
NAC 600–1,800 mg/day is the best second intervention for glutathione depletion-driven liver damage from acetaminophen, alcohol, or oxidative stress — the TUDCA+NAC combination covers ER stress, bile acids, glutathione synthesis, and Nrf2 activation simultaneously is another option worth comparing when its evidence and constraints better match the decision at hand. no liver supplement substitutes for lifestyle intervention in metabolic NAFLD — caloric deficit, reduced fructose/refined carbohydrate intake, and regular exercise remain primary interventions; supplements protect hepatocytes and reduce enzyme elevation but do not eliminate hepatic fat accumulation driven by dietary patterns. Treat the ordering as a research aid, then verify population fit, contraindications, alternatives, and objective response with appropriate professional review when the decision is medically consequential.
Related ProtocolRank Articles
Best Berberine Supplements Ranked
Deep dive into berberine forms, dosing, and evidence for blood sugar, NAFLD, and metabolic syndrome.
Best Supplements for Blood Sugar Management Ranked 2026
8 supplements for blood sugar management ranked by mechanism specificity and HbA1c/fasting glucose evidence — berberine, magnesium, chromium, and more.
Best Supplements for Weight Loss Ranked 2026
Protein powder, berberine, glucomannan, and five more weight loss supplements ranked by clinical evidence for fat mass reduction.
Best Anti-Aging Supplements for Men Ranked 2026
NMN, resveratrol, spermidine, and more ranked by senolytic, NAD+, and mitochondrial longevity mechanisms.
Best Supplements for Cortisol Management Ranked 2026
Ashwagandha, phosphatidylserine, rhodiola, and five more cortisol management supplements ranked by HPA axis evidence.
Curcumin Supplements: Evidence, Labels & Safety
Bioavailability-enhanced curcumin forms ranked — phytosome, BCM-95, nanoparticle, and piperine complex compared for NF-κB inhibition.
Best Magnesium Supplements Ranked 2026
Magnesium glycinate, L-threonate, malate, and five more forms ranked by bioavailability, sleep, metabolic, and neuroprotective evidence.
Best Supplements for Insulin Resistance Ranked 2026
Berberine, inositol, ALA, and five more supplements ranked for insulin receptor signaling and glucose disposal evidence.
Best Ashwagandha Supplements Ranked 2026
KSM-66, Sensoril, and root extract forms ranked for adaptogenic, cortisol, and thyroid evidence.
Further Reading from Our Sister Sites
Alive Longevity
Alive Longevity: Longevity Supplement Guides
Research-backed supplement explainers and buyer guides for stacking decisions.
Peaked Labs
Peaked Labs: TRT Provider Comparisons
Compare telehealth TRT provider models, monitoring cadence, and total program costs.
Alive Longevity
Alive Longevity: Ingredient Deep Dives
Deep dives on high-interest ingredients like omega-3s, collagen, and magnesium forms.
Liver Support Supplement FAQ
What is the best liver supplement for NAFLD (fatty liver)?
For NAFLD, the highest-evidence OTC stack is TUDCA + NAC + Berberine. TUDCA (500 mg/day) directly inhibits the ER stress that drives hepatocyte death in fatty liver and is the only OTC liver supplement with RCT evidence showing 30–49% ALT reduction in NAFLD. NAC (600–1,200 mg/day) addresses the glutathione depletion and oxidative stress that amplify NAFLD-related liver damage. Berberine (500 mg 3x daily) blocks de novo lipogenesis — the primary metabolic driver of fat accumulation in the liver — via AMPK activation and SREBP-1c suppression. All three mechanisms are complementary and non-overlapping.
Is milk thistle actually effective, or is it overhyped?
Milk thistle (silymarin) is evidence-based but often under-dosed and poorly absorbed. The clinical literature supports its hepatoprotective effects across cirrhosis, viral hepatitis, and toxic hepatopathy at 420 mg/day of standardized extract (70–80% silymarin). The standard capsules sold in health food stores often have poor bioavailability — phosphatidylcholine-complexed silymarin (silybin-PC, Siliphos) improves absorption 4–5x. Milk thistle's unique mechanism — inhibiting TGF-β1-driven hepatic stellate cell activation to prevent fibrosis — is not replicated by TUDCA or NAC, making it a valuable third pillar of a comprehensive liver stack even if it is not the most potent first-line choice for acute NAFLD.
Can I take TUDCA, NAC, and milk thistle together?
Yes — TUDCA, NAC, and milk thistle have no known drug interactions with each other and work through entirely non-overlapping mechanisms (bile acid/ER stress, glutathione synthesis, Nrf2/anti-fibrotic respectively). This combination is the most evidence-supported OTC liver stack available. Add berberine if metabolic syndrome or insulin resistance is a concurrent issue. Take all with food to minimize GI side effects.
How quickly do liver supplements reduce elevated liver enzymes?
Based on clinical trial timelines: NAC at 600–1,800 mg/day typically produces measurable ALT/AST reductions within 4–8 weeks; TUDCA at 500 mg/day shows significant enzyme normalization at 3 months in NAFLD studies; milk thistle (silymarin 420 mg/day) shows measurable reductions in most trials within 8–12 weeks; berberine (500 mg TID) shows metabolic NAFLD improvement within 12 weeks. Baseline and 90-day follow-up on a CMP (comprehensive metabolic panel) is the recommended monitoring approach — liver enzyme tests cost ~$15 via direct-to-consumer labs.
Does NAC raise glutathione effectively when taken orally?
Yes — oral NAC reliably raises hepatic glutathione. A 600 mg oral dose raises hepatic glutathione by 30–50% within 2 hours in GSH-depleted subjects (Lauterburg et al.). The IV form used in emergency medicine for acetaminophen overdose is used because of faster delivery in acute toxicity, not because the oral form is ineffective — for chronic liver support, oral NAC at 600–1,800 mg/day is well-established as the clinically effective form.
Is choline deficiency actually a cause of fatty liver?
Yes — choline deficiency is one of the most established dietary causes of fatty liver. Controlled feeding studies (Buchman et al. 2001, Zeisel et al. 2007) demonstrate that choline-deficient diets cause measurable hepatic steatosis in healthy humans within 6 weeks, reversible by choline repletion. The mechanism is direct: choline is required for phosphatidylcholine synthesis, which is required for VLDL assembly, which is required for hepatic triglyceride export. Without adequate choline, triglycerides cannot leave the liver. Since 90% of Americans consume below the AI (550 mg/day for men, 425 mg/day for women), choline repletion through eggs or PC supplementation may be the most impactful and lowest-cost liver intervention for many people.
Does berberine interact with any medications?
Yes — berberine inhibits CYP2D6 and CYP3A4, two cytochrome P450 enzymes that metabolize a large number of prescription medications. This means berberine can raise plasma levels of co-administered drugs metabolized by these enzymes (antidepressants, beta-blockers, statins, antifungals, and many others). Always review current medications for CYP2D6/3A4 interactions before starting berberine. Additionally, berberine should not be combined with blood sugar-lowering medications (metformin, sulfonylureas, insulin) without glucose monitoring, as additive blood sugar-lowering effects can cause hypoglycemia.
What liver tests should I get to track whether supplements are working?
The standard liver enzyme panel is: ALT (alanine aminotransferase), AST (aspartate aminotransferase), GGT (gamma-glutamyl transferase), and alkaline phosphatase — all included on a standard comprehensive metabolic panel (CMP). ALT and AST are the most sensitive markers of hepatocyte damage; GGT is particularly sensitive to alcohol and cholestatic stress; alkaline phosphatase reflects bile duct and bone turnover. For NAFLD specifically, a FIB-4 score (calculated from ALT, AST, age, and platelet count) provides a non-invasive fibrosis estimate. Get baseline labs before starting any liver supplement protocol, and retest at 90 days to assess response.